Please provide your email address to receive an email when new articles are posted on . The myriad manifestations of herpes simplex keratitis can be difficult to diagnose without a high suspicion, but ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

In a recent study published in the Virology Journal, a group of researchers evaluated the antiviral efficacy and therapeutic potential of harmol in treating herpes simplex virus type 1 (HSV-1) induced ...

SAN FRANCISCO, April 22, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious ...

Researchers from Excision Biotherapeutics Inc. and affiliated organizations have reported the development of a novel CRISPR/Cas9-mediated genome editing therapy – EBT-104 – for the treatment of latent ...

- Excision’s proprietary gene editing technology holds unique, curative potential to address the leading cause of corneal blindness in the United States - Global incidence of HSV keratitis is ...

Compr Ophthalmol Update. 2005;6(2):85-101. In a 10-week study of three times daily oral acyclovir against placebo, pediatric patients with HSV stromal keratitis who were treated concomitantly with ...

- Treatment with EBT-104 led to complete elimination of viral shedding in 92% eyes of treated rabbits - Excision’s proprietary gene editing technology holds unique, curative potential to address the ...